New vaccine aims to stop rare but deadly brain infections

NCT ID NCT06899802

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 21 times

Summary

This study tests a new vaccine designed to protect healthy adults from two rare but serious mosquito-borne viruses that can cause brain swelling (encephalitis). The trial involves 411 participants and aims to find the best dose and schedule for the vaccine. Researchers will measure the body's immune response and monitor for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENCEPHALITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Benchmark Research

    Sacramento, California, 95864, United States

  • Benchmark Research

    Kenner, Louisiana, 70065, United States

  • Benchmark Research

    San Angelo, Texas, 76904, United States

  • Clay-Platte Family Medicine, P.C./CCT Research

    Kansas City, Missouri, 64151, United States

  • Jefferson City Medical Group / Avacare

    Jefferson City, Missouri, 65109, United States

  • Johnson County Clin-Trials

    Lenexa, Kansas, 66219, United States

  • Lifeline Primary Care, Inc. / CCT Research

    Lilburn, Georgia, 30047, United States

  • Papillion Research Center/CCT Research

    Papillion, Nebraska, 68046, United States

  • Versailles Family Medicine, PLLC/CCT Research

    Versailles, Kentucky, 40383, United States

Conditions

Explore the condition pages connected to this study.